![CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol | World Pharma Today CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol | World Pharma Today](https://www.worldpharmatoday.com/wp-content/uploads/2018/06/images_article_pressrelease_Entecavir-Cilostazol.jpg)
CASI Pharmaceuticals Enters Strategic Partnering And Contract Manufacturing Agreement With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol | World Pharma Today
![CASI - CASI Pharmaceuticals, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqCM) CASI - CASI Pharmaceuticals, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqCM)](https://images.fintel.io/us-casi-so.png)
CASI - CASI Pharmaceuticals, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqCM)
![Alert: Major Price Advance (8/10/22)-CASI Pharmaceuticals Inc (NASDAQ: CASI). - PriceTarget Research Alert: Major Price Advance (8/10/22)-CASI Pharmaceuticals Inc (NASDAQ: CASI). - PriceTarget Research](https://pricetargetresearch.com/wp-content/uploads/2022/08/out_mm25510.jpg)
Alert: Major Price Advance (8/10/22)-CASI Pharmaceuticals Inc (NASDAQ: CASI). - PriceTarget Research
![CASI Pharmaceuticals Partner, BioInvent, Announces BI -1206 Granted Orphan Drug Designation By The U.S. FDA For The Treatment Of Patients With Follicular Lymphoma | BioBuzz CASI Pharmaceuticals Partner, BioInvent, Announces BI -1206 Granted Orphan Drug Designation By The U.S. FDA For The Treatment Of Patients With Follicular Lymphoma | BioBuzz](https://biobuzz.io/wp-content/uploads/2022/01/CASI_HR-1024x426.png)